Chapter 11 of 25
Start with the purpose of treatment
Curative treatment aims to remove or destroy the cancer permanently. Disease-controlling treatment aims to shrink cancer or slow its growth when cure is unlikely. Symptom-relieving treatment addresses problems such as pain, bleeding or difficulty swallowing. These goals can overlap: someone receiving curative treatment still needs excellent symptom care. Ask the team to explain the main goal in clear words and to revisit it if circumstances change.
A stage number alone cannot choose treatment. The same stage can mean different things in the mouth, voice box or HPV-associated throat cancer. A cancer that can be removed safely may have a different pathway from one involving vital structures. “Unresectable” means surgery cannot remove the cancer acceptably; it does not automatically mean that all curative treatment is impossible.
Meet the multidisciplinary team
A head and neck surgical oncologist assesses removal and reconstruction. A radiation oncologist plans radiation, and a medical oncologist considers chemotherapy, immunotherapy and targeted medicines. The radiologist interprets scans and the pathologist identifies the cancer in tissue. Together they compare the options at a multidisciplinary team meeting, sometimes called a tumour board.
The supporting team is equally important. A dietitian helps protect weight and strength. A speech and swallowing therapist assesses communication, safe swallowing and rehabilitation. Dental specialists prepare the mouth for treatment and plan long-term care. Nurses coordinate practical care; physiotherapists address shoulder movement, stiffness and swelling. Pain, palliative-care and psycho-oncology teams help with symptoms, distress and family needs.
What changes the recommendation?
The team considers the exact starting site, tissue type, tumour extent, lymph nodes and any distant spread. HPV status has a specific role in oropharyngeal cancer; it cannot be applied to every head and neck tumour. Previous surgery or radiation changes what can be done safely. The anticipated effects on voice, swallowing, breathing and appearance matter alongside the likelihood of controlling cancer.
Fitness is assessed through everyday activity, nutrition and medical conditions, rather than age alone. Kidney function, hearing loss and nerve symptoms influence whether cisplatin is suitable. Heart or lung disease may change anaesthetic risks. Autoimmune illness, a transplanted organ or previous serious immune toxicity may complicate immunotherapy. Tell the team about every medicine, supplement and traditional remedy.
Making a shared decision
Ask the team to compare the likely benefits, serious risks, length of treatment and expected recovery for each reasonable option. If surgery and radiotherapy are both possible, ask whether either choice might still require the other afterward. Preserving an organ is not always the same as preserving its function: a voice box that remains in place may still have difficulty protecting the airway.
It is reasonable to discuss work, travel, family responsibilities, finances and access to treatment. In India, daily travel for radiotherapy, nutritional support and eligibility for financial assistance may need planning early. Across countries, drug licences and insurance coverage differ. Practical constraints deserve support, but they should be discussed openly rather than allowing a curative course to stop unexpectedly.
Prepare for the planning visit
Bring the biopsy report, slides or tissue-block transfer information if requested, scans and reports, medication list, previous treatment records and a short list of priorities. Write down whom to call after hours. Ask whether dental care, swallowing assessment, nutritional support or fertility advice is needed before treatment begins.
A second specialist opinion can help when several major options exist or the diagnosis is unusual. Arrange it promptly and share the complete records. If breathing is threatened, bleeding is substantial or fluids cannot be swallowed, urgent stabilization takes priority over a routine second-opinion appointment. An agreed plan should include a start date, monitoring arrangements, response assessment and rehabilitation, not just the name of an anticancer treatment.
References and evidence review
- NCI: Treatment of Head and Neck Cancer in Adults, current PDQ summaries
- ASTRO clinical practice guideline: HPV-positive oropharyngeal cancer (2024)
- NCI: Lip and Oral Cavity Cancer Treatment PDQ (2025)
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.